Jump to content

COVID-19

Edit links
From Wikipedia
COVID-19
emerging communicable disease, atypical pneumonia, class of disease
Official namecoronavirus disease Edit
Significant personZhang Jixian, Zhong Nanshan Edit
Significant eventCOVID-19 pandemic Edit
Has causeSARS-CoV-2 Edit
Time of discovery anaa inventionDecember 2019 Edit
Location of discoveryWuhan Edit
Health specialtyinfectious diseases, pulmonology, virology, epidemiology, emergency medicine Edit
Medical examinationreverse transcription polymerase chain reaction, ELISA, computed tomography, polymerase chain reaction, COVID-19 rapid antigen test Edit
HashtagCOVID19 Edit
Has natural reservoirmink Edit
Get characteristiccontagiousness, COVID-19 mortality Edit
History of topictimeline of the COVID-19 pandemic Edit
Subject has roleacute respiratory distress syndrome Edit
Manifestation ofdisease X Edit
Handled, mitigated, or managed bytreatment of COVID-19 Edit
EntitySchema for this classEntity schema not supported yet (E196) Edit
NCI Thesaurus IDC171133 Edit

Coronavirus disease 2019 (COVID-19, dem sanso know am as SARS-2) be a contagious disease wey be caused by de coronavirus SARS-CoV-2. Insyd January 2020, na de disease spread worldwide, wey result in de COVID-19 pandemic.

De symptoms of COVID‑19 fi vary buh often dey include fever,[1] fatigue, cough, breathing difficulties, loss of smell, den loss of taste.[2][3][4] Symptoms fi begin one to fourteen days after exposure to de virus. At least a third of people wey be infected no dey develop noticeable symptoms.[5][6] Of those wey develop symptoms noticeable enough make dem be classified as patients, chaw (81%) dey develop mild to moderate symptoms (up to mild pneumonia), while 14% dey develop severe symptoms (dyspnea, hypoxia, anaa more dan 50% lung involvement on imaging), den 5% dey develop critical symptoms (respiratory failure, shock, anaa multiorgan dysfunction).[7] Older people get a higher risk of dem dey develop severe symptoms. Sam complications dey result in death. Sam people continue dey experience a range of effects (long COVID) for months anaa years after infection, wey na dem observe damage.[8] Multi-year studies for de long-term effects dey go on.[9]

Testing methods for COVID-19 make dem detect de virus ein nucleic acid dey include real-time reverse transcription polymerase chain reaction (RT‑PCR),[10][11] transcription-mediated amplification,[10][11][12] den reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[10][11] from a nasopharyngeal swab.[13]

References

[edit | edit source]
  1. ↑ Islam MA (April 2021). "Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients". PLOS ONE. 16 (4): e0249788. Bibcode:2021PLoSO..1649788I. doi:10.1371/journal.pone.0249788. PMC 8023501. PMID 33822812.
  2. ↑ Saniasiaya J, Islam MA (April 2021). "Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients". The Laryngoscope. 131 (4): 865–878. doi:10.1002/lary.29286. ISSN 0023-852X. PMC 7753439. PMID 33219539.
  3. ↑ Saniasiaya J, Islam MA (November 2020). "Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients" (PDF). Otolaryngology–Head and Neck Surgery. 165 (1): 33–42. doi:10.1177/0194599820981018. PMID 33320033. S2CID 229174644.
  4. ↑ Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R (August 2020). "Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis". Mayo Clin. Proc. 95 (8): 1621–1631. doi:10.1016/j.mayocp.2020.05.030. PMC 7275152. PMID 32753137.
  5. ↑ Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, et al. (March 2023). "Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis". The Pediatric Infectious Disease Journal. 42 (3): 232–239. doi:10.1097/INF.0000000000003791. PMC 9935239. PMID 36730054.
  6. ↑ Oran DP, Topol EJ (January 2021). "The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review". Annals of Internal Medicine. 174 (5): M20-6976. doi:10.7326/M20-6976. PMC 7839426. PMID 33481642.
  7. ↑ "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
  8. ↑ Davis HE, McCorkell L, Vogel JM, Topol EJ (March 2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews. Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC 9839201. PMID 36639608.
  9. ↑ CDC (11 February 2020). "Post-COVID Conditions". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 12 July 2021.
  10. ↑ 10.0 10.1 10.2 "Overview of Testing for SARS-CoV-2, the virus that causes COVID-19". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 31 July 2022.
  11. ↑ 11.0 11.1 11.2 "Nucleic Acid Amplification Tests (NAATs)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 31 July 2022.
  12. ↑ Gorzalski AJ, Tian H, Laverdure C, Morzunov S, Verma SC, VanHooser S, et al. (August 2020). "High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2". Journal of Clinical Virology. 129: 104501. doi:10.1016/j.jcv.2020.104501. PMC 7286273. PMID 32619959.
  13. ↑ Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B (November 2020). "Laboratory diagnosis of coronavirus disease-2019 (COVID-19)". Clinica Chimica Acta; International Journal of Clinical Chemistry. 510: 35–46. doi:10.1016/j.cca.2020.06.045. PMC 7329657. PMID 32621814.

Read further

[edit | edit source]
[edit | edit source]

Health agencies

[edit | edit source]

Directories

[edit | edit source]

Medical journals

[edit | edit source]

Treatment guidelines

[edit | edit source]
Dem retrieve am from "https://gpe.wikipedia.org/w/index.php?title=COVID-19&oldid=57594"